Biomab Egfr 50mg Injection

About

Biomab Egfr 50mg Injection is a monoclonal antibody therapy specifically designed to target the Epidermal Growth Factor Receptor (EGFR), a protein often overexpressed on the surface of various cancer cells. By binding to EGFR, this medication blocks the signaling pathways that promote cell growth, proliferation, and survival, thereby inhibiting tumor development and progression. It is a form of targeted therapy used in the treatment of certain types of cancer, particularly those where EGFR overexpression or mutation plays a significant role in disease pathology. As an injection, it is administered intravenously, allowing for direct systemic delivery. Biomab Egfr aims to provide a more precise anti-cancer effect, often used alone or in combination with chemotherapy, to improve patient outcomes and manage advanced stages of cancer. Close monitoring for infusion reactions and other side effects is essential during treatment.

Uses

• Treatment of specific EGFR-expressing solid tumors.
• Management of metastatic colorectal cancer.
• Treatment of head and neck squamous cell carcinoma.
• Inhibition of cancer cell growth and proliferation.

Directions For Use

This medication is administered as an intravenous infusion by a healthcare professional. The dosage and frequency will be determined by your doctor based on your condition.

Benefits

• Targets specific cancer cell pathways.
• Effective in EGFR-positive cancers.
• Can be used alone or in combination therapy.
• May improve progression-free and overall survival.
• Offers a targeted approach to cancer treatment.
• Helps to control tumor growth and spread.

Side Effects

• Skin rash (acneiform)
• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Infusion-related reactions
• Hypomagnesemia
• Dry skin
• Pruritus
• Paronychia
• Headache
• Stomatitis

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may worsen general health and side effects. Consult your doctor.
• Pregnancy - Not recommended during pregnancy due to potential fetal harm. Women of childbearing potential should use effective contraception.
• Breastfeeding - Avoid breastfeeding during treatment and for a period after the last dose, as the drug may be excreted in breast milk and pose risks to the infant.
• Liver - Use with caution in patients with pre-existing liver conditions. Liver function should be monitored periodically during treatment.
• Kidney - Generally considered safe in patients with renal impairment, but caution is advised. No specific dose adjustment typically required.
• Lung - Monitor for signs of interstitial lung disease (ILD) or pneumonitis, though rare. Discontinue if severe pulmonary symptoms occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.